Member Info for OAPK20

Is it agents or financiers holding the sale back ?

Healthy pull back. Profits profit no harm taking it for some. Top up if you feel the opportunity is good. A lot have bagged haven’t they ?

.

Tech - dependent on your risk appetite

See Dec 27th 2023 RNS latest results and TR1 - AUK.

DYOR

Apologies to this BB

Seen June mentioned Tech fwiw.

Nice to have your opinion Tech.

Overhang not cleared yet ?

Wasn’t luck enough to get the low. Last few days have been decent.

Is it FDA approval driving this alone or is there a contract in the pipe for the NHS off the back of NICE approval?

Is GENI talking. ?

The ROCA test uses a proprietary algorithm to calculate a woman's individual OC risk based on several clinical factors including age and accumulating Cancer Antigen 125 (CA-125) blood test results. The ability of the ROCA test to interpret changes in an individual's CA-125 level over time through four monthly interval testing was recognised by the NICE committee as an important contributor to its accuracy and ability to detect OC earlier. Additionally, the NICE committee recognised the published evidence that surveillance using the ROCA test would have a cost-saving benefit for the NHS.

Tech

30 months or 2 1/2 YEARS …….😳

Green

Not comparing the companies. Refer to the events. CDT coffers were emptied by the MURPH holders, which says all about what they thought of CDT in the short term,

Do you think US HNWI’s will pay US$0.3 million on signing the binding agreement and a further US$1.0 million on each of the fifteenth and thirtieth month anniversaries of signing, if CIZ are still developing new antibodies to extend the range and proprietary rights that the Company has for detecting the CIZ1B Biomarker.?

Unless CIZ finalise the final antibody to accredited quality standards AND actually update current shareholders what’s going to happen ?

VV

All positive but the only thing that is needed is confirmation that they have entered the scale-up and manufacturing phase and confirmed the main components of the Company's proposed commercial test for CIZ1B, standard production and operating protocols have been finalised and clinical trials have commenced that should lead to an accredited Laboratory Developed (LDT) test for launch initially in the USA.

Anything else is Hopium, fluff and pumping for the Placees

The full quote reads a little differently does it not ? So if the US HNWI's don't like the look of it (For example SEE CDT) then what ?

BIO's ability to meet its financial obligations is dependant on a group of sophisticated high net worth investors in the USA.

Also is it not just a 2 person Board as it stands ?

Mr Behnke will be joined on the Board of BIO by Dr Ron Greeno, a veteran physician executive with 30 years of experience in the hospitalist practice management field. He was the founder of Cogent Healthcare and served as its EVP for strategy and Chief Medical Officer until its merger with Sound Physicians.

Makes you wonder about future and raises delisting then relisting thoughts. Easier to raise across the pond.

Green. “ Not sure any long term PIs are taking profit at this price…”

On this occasion I know.

Wonder why

Yeah ok. Placees couldn’t possibly comprehend that PI’s are taking profit below the placing price because they bought at nearly 50% discount to the placing and have held for so long theyve finally got sick of no replies to emails from CIZ or the other one and are derisking/selling out.

To think they thought that RNS would create enough volume for Placees to flip to PI’s to catch their bag.

Not too excited. It’s BB’s company run from the house. Not exactly BioTechne is it

Key Highlights

· The MoU envisages Cizzle providing an exclusive licence to BIO to develop and market clinical diagnostic assays based on the CIZ1B biomarker to facilitate the early detection of lung cancer in North America

· Cizzle will receive an up-front payment of US$100,000 within 30 days as a non-refundable fee to grant BIO an exclusive negotiating period of 120 days

· Subject to entering binding documentation, Cizzle will receive minimum advance royalty payments of US$2.3 million over a period of 30 months, payable as to US$0.3 million on signing the binding agreement and a further US$1.0 million on each of the fifteenth and thirtieth month anniversaries of signing as part of annual royalty fees of 10% of net sales

· BIO intends to fully fund all expenditure on development, clinical trials, accreditation and marketing of diagnostic tests for the CIZ1B Biomarker in North America which would represent a significant saving on current planned expenditure by the Company

· Cizzle will participate in the ownership of BIO through a grant of a 10% equity stake in BIO for no cash consideration

· Cizzle will benefit from inventions and improvements to CIZ1B technology for sale in the rest of the world

Allenby Capital Ltd 32 Claridge House, Davies St, London, W1K 4ND,

Is that Mayfair or Marylebone. Is Oxford street the border? Londoners out there ….

Guessing Project Mayfair would’ve been tooooooo obvious.

I don’t claim to have contact with the company or to have “exchanged mobile numbers”

On another note Placees aren’t going to be happy with the share price. There’s a lot of pumping needed to flip and clear this overhang.